What is triple-negative breast cancer

Triple-negative breast cancer "refers specifically to the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) were negative breast cancer patients. Poor prognosis, 5-year survival rate less than 15% more common in younger patients, visceral metastasis, a higher risk of brain metastasis, histological grade, mostly three, a higher proportion of cell proliferation, c-kit, p53, EGFR expression and more positive for basal cell markers CK5 / 6, CK17 is also more positive for the tumor-invasive, easy to local recurrence and distant metastasis with basal-like breast cancer and the BRCA1 gene mutation in breast cancer have more similar characteristics.
  "Triple-negative breast cancer" endocrine therapy and trastuzumab targeted therapy, the treatment relies on chemotherapy. Compared with other types of breast cancer, triple negative breast cancer patients chemotherapy, radiation sensitivity is higher, but if only the conventional standard treatment, the prognosis is still poor, relapse-free survival and overall survival is low. Some targeted prospective clinical trials currently under way, so most information comes from retrospective subgroup analysis of studies or trials. There is no treatment for triple negative breast cancer guidelines, the treatment is generally poor prognosis of breast cancer by routine, choice of adjuvant chemotherapy with anthracycline taxane solution. Receiving neoadjuvant chemotherapy with anthracycline and taxane neoadjuvant chemotherapy, the availability of a higher pathologic complete remission rate. Platinum drugs for neoadjuvant chemotherapy are being studied. Metastatic triple-negative breast cancer, the rapid progression of the disease, palliative chemotherapy study are the following: microtubule stabilizing agent Paclitaxel, Docetaxel, nab-paclitaxel, ixabepilone; carboplatin / cisplatin; anti-angiogenesis Bevacizumab, Sunitinib; EGFR inhibitors Cetuximab, Erlotinib and so on.
  In short, the "triple-negative breast cancer" on the poor efficacy of conventional therapy, high incidence of recurrence and metastasis, survival rate, physicians need to be concerned about cancer and clinical research, new treatment options to be proposed and evaluated.

Posted in Triple-negative breast cancer